KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Non Operating Income: 2010-2025

Historic Non Operating Income for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to -$18.9 million.

  • Emergent BioSolutions' Non Operating Income fell 124.26% to -$18.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.3 million, marking a year-over-year increase of 209.16%. This contributed to the annual value of -$34.2 million for FY2024, which is 484.27% down from last year.
  • Emergent BioSolutions' Non Operating Income amounted to -$18.9 million in Q3 2025, which was down 2.72% from -$18.4 million recorded in Q2 2025.
  • Emergent BioSolutions' Non Operating Income's 5-year high stood at $77.9 million during Q3 2024, with a 5-year trough of -$66.3 million in Q2 2024.
  • Moreover, its 3-year median value for Non Operating Income was -$18.1 million (2024), whereas its average is $645,455.
  • In the last 5 years, Emergent BioSolutions' Non Operating Income surged by 495.37% in 2023 and then plummeted by 703.33% in 2024.
  • Over the past 5 years, Emergent BioSolutions' Non Operating Income (Quarterly) stood at -$9.9 million in 2021, then surged by 38.38% to -$6.1 million in 2022, then surged by 149.18% to $3.0 million in 2023, then tumbled by 703.33% to -$18.1 million in 2024, then tumbled by 124.26% to -$18.9 million in 2025.
  • Its last three reported values are -$18.9 million in Q3 2025, -$18.4 million for Q2 2025, and $69.7 million during Q1 2025.